A 100% import tariffs on branded and patented pharmaceuticals announced by U.S. President Donald Trump, effective October 1, 2025, has jolted global pharma. But India’s generic-heavy exporters are expected to be largely insulated at the outset, analysts say, even as risks lurk if the levy’s scope widens.
The Announcement
Trump said the tariff would apply to any branded or patented drug unless the manufacturer is “IS BUILDING” a U.S. plant, defined as projects that have broken ground or are under construction. Firms with construction underway would be exempt.
Why India’s generic exporters are (mostly) spared
India primarily ships low-cost, unbranded generics to the U.S., placing most exporters outside the tariff’s crosshairs at launch, according to industry commentary. However, experts caution that any future expansion to complex generics or biosimilars could bite.
Motilal Oswal’s Tushar Manudhane expects no impact on generic exports from India given the tariff’s focus on branded/patented drugs; even CDMO firms largely supply components rather than finished formulations, he noted.
Founder and Director of Bionova Group Mr. Suddhir Jain noted, “The tariffs imposed by the States on pharma are blatant protectionist barriers that will harm patients far more than industries. For decades, India has been the world’s pharmacy, supplying life-saving medicines at a fraction of Western costs. Such moves only expose America’s inability to match India’s efficiency and quality. Rather than yielding, India must intensify innovation, expand manufacturing of products that are still import-dependent and assert itself as the true global pharma powerhouse. The urgent priority now is massive investment in fully integrated, indigenous API manufacturing to secure complete self-reliance.
Market reaction and why a rebound is on watch
The tariff post sparked panic selling on Friday in Indian pharma shares, but analysts expect a sharp rebound as investors digest that most Indian shipments are generic and thus outside the levy. Names like Sun Pharma, Aurobindo, Cipla, Dr Reddy’s, Gland, Zydus and Lupin together account for roughly 70% of India’s U.S. pharma exports and are seen rebounding as clarity spreads.
The exposure map: where risks could crystallise
- Sun Pharma: Rising U.S. specialty/branded portfolio, global specialty sales ~$1.2 bn in FY25 (~20% of revenue), could see sensitivity if exemptions don’t apply to specific SKUs, analysts told ET.
- Dr Reddy’s: 47% of earnings come from the U.S., the highest among peers; Nomura sees U.S. earnings at $1.5 bn in FY26, making policy shifts consequential.
- Lupin: Projects $1.1 bn U.S. revenues in FY26; its U.S. manufacturing contributes $70–80 mn (6–7% of total earnings).
The U.S. constituted 34.6% of India’s total drug exports in FY25. Monthly exports to the U.S. dipped from $745 mn (May 2025) to $646.6 mn (Aug 2025) amid trade tensions and a delayed bilateral trade deal, underscoring why tariff design details matter.
Next Checkpoints
Two variables will shape the real-world impact:
- Fine print / executive order: Market watchers are explicitly waiting for the formal order to parse product coverage and carve-outs.
- Section 232 probe: The tariff push coincides with a U.S. Section 232 review assessing whether pharma imports pose national-security risks, policymaking that could influence scope and timelines.
Several reports suggest a broader onshoring agenda in the U.S., with a final decision expected early next year, but companies are emphasising that it’s “too early to rule out anything” without the order text.
The tariff is a headline shock with narrow initial reach. India’s generic exporters should keep shipping, but policy creep, to biosimilars or complex generics, would change the calculus quickly. For investors and operators alike, the executive order text and the Section 232 trajectory are now the only documents that matter.
Also Read: How Tariffs on Indian Medical Supplies May Backfire on the U.S.
